EU pharma sectors.

Understanding the Foundations: Good Documentation Practice (GDP) and Regulatory Context

Before delving into practical writing steps, it is imperative to understand the fundamental principles governing pharmaceutical documentation. Good documentation practice (GDP) establishes standards to ensure all records are reliable, accurate, and available for review during internal audits or regulatory inspections.

The core principles of GDP are encapsulated in the ALCOA+ criteria, which stand for:

• Attributable – The author of each record entry must be clearly identifiable.
• Legible – Records must be readable and permanent.
• Contemporaneous – Documentation must be recorded at the time the activity is performed.
• Original – The original record or a certified true copy must be retained.
• Accurate – Records should be true and free from errors and omissions.
• Complete – All relevant data must be recorded without gaps.
• Consistent – Entries must be made in a standard format and follow procedural norms.
• Enduring – Records must be maintained for the required retention period without alteration.
• Available – Documents must be accessible for review when required.

The FDA’s 21 CFR Parts 210 and 211, the EMA’s EU GMP Volume 4 Annex 11, and PIC/S PE 009 outline documentation expectations. These requirements emphasize traceability and transparency within EU GMP guidelines, which also address electronic data integrity in systems such as Electronic Batch Records (EBR).

In the pharmaceutical quality system, documentation serves as evidence that all procedures, investigations, and manufacturing processes occurred as intended. The value of batch records and investigation logs lies not only in recording outcomes but also in accurately describing the rationale or observations surrounding deviations or quality events.

Step 1: Preparing to Write – Gathering Relevant Information for Objective Documentation

Proper preparation is the first essential step to writing objective, factual notes. This requires gathering all relevant documentation, data, and context before committing text to paper or an electronic system. Key preparation activities include:

• Review the Batch Record and Associated Documentation: Start by examining the master batch record (MBR), production records, prior inspection reports, and any preliminary investigation notes related to the event or process in question.
• Clarify the Purpose of the Note: Determine whether the note is intended for an investigation report, batch log, deviation record, or quality review. Different contexts may require varying levels of detail or format.
• Ensure Access to Relevant Data Systems: For investigations related to manufacturing or testing, access to laboratory data management systems, EBRs, or electronic Quality Management Systems (eQMS) may be necessary to verify facts.
• Identify the Responsible Persons: Know who is responsible for original inspection, data entry, and review so that observation and attribution can be clear and credible.

Gathering comprehensive context will prevent omissions and reduce the risk of incorrect assumptions or biased statements that may undermine inspection readiness or government audits.

Step 2: Writing Objective Notes According to ALCOA+ Principles

When drafting notes for investigations or batch records, the following stepwise guidelines help maintain objectivity and compliance with GDP standards:

Attributable and Legible Entries

Every hand-written or electronic note must clearly identify the author. This includes full name, signature, or electronic authentication timestamp. Use clear, professional handwriting if manually recorded. Avoid ambiguous initials unless they are officially registered and understood within the organization.

Contemporaneous Documentation

Notes should be made immediately or as soon as reasonably possible after the event occurs. Avoid retrospective entries or “back-dating,” as these practices violate GMP and may raise questions during inspection. Where delays are unavoidable, document the reason for the delay transparently.

Original and Accurate Content

Ensure writing reflects exact observations or facts verified through data or direct witness. Do not speculate, assume causes, or include subjective language such as “I think” or “probably.” Use consistent scientific terminology and measurements. For example, “Sample temperature was recorded at 22.4°C at 10:15 AM” is preferable over “Sample seemed warm.”

Complete and Consistent Documentation

Include all relevant information without omission. This includes dates, times, batch or lot numbers, equipment identifiers, and reference to related documents where necessary. If certain sections are not applicable, note that explicitly (e.g., “No deviations noted during inspection”). Maintain consistency with previous notes or reports to avoid conflicting information.

Enduring and Available Records

Use indelible ink for paper records or secure fields for electronic notes that prevent erasures or deletions without audit trail. Amendments or corrections should be made by striking through the original text with a single line without obscuring it, followed by a clear reason and initials plus date. This retains data integrity and supports traceability.

Adopting this disciplined approach ensures notes can reliably support investigations and are defensible during regulatory scrutiny.

Step 3: Structuring Notes for Investigations and Logs with Clear Language

Structured, concise writing is critical to ensure clarity and usefulness of investigation notes and batch record entries. Follow this recommended format:

• Heading/Title: Identify the nature of the note clearly (e.g., “Investigation Note: OOS Result for Batch #12345” or “Deviation Log Entry: Equipment Failure on 15-Jun-2024”).
• Date and Time: State when the note is made and the time of the event or observation, if different.
• Author Identification: Include name and role, e.g., “Written by John Smith, QA Analyst.”
• Background or Context: Briefly summarize the relevant background, e.g., “During routine sampling, an out-of-specification (OOS) result was detected…”
• Factual Observations: Present only relevant facts observed, measurements taken, or data reviewed, avoiding interpretation or assumptions.
• Actions Taken: Note immediate steps executed to investigate or mitigate, such as “Sample re-tested per SOP” or “Equipment taken offline for maintenance.”
• Pending Actions or Follow-Up: Record any open investigations or next steps, including responsible persons and due dates.
• References to Supporting Documents: Cross-reference batch records, lab notebooks, deviation reports, or data printouts as applicable.

Example of a clear investigation note excerpt:

Investigation Note: Temperature Excursion in Storage Area
Date/Time: 16-Jun-2024 14:45
Author: Sarah Thompson, QA Specialist
Background: During routine environmental monitoring, temperature in storage room #3 exceeded 25°C for 45 minutes.
Observations: Data logger #S3-045 recorded a peak temperature of 27.2°C between 13:30 and 14:15. No alarms were triggered.
Actions Taken: Temperature excursion documented in deviation report DR-789. Products were quarantined pending assessment.
Follow-Up: Investigation ongoing; maintenance team contacted to verify HVAC functionality.
References: Data logger report (S3-045-061624), Deviation DR-789.

Using standard technical language and avoiding unnecessary jargon improves readability for inspectors and cross-functional teams.

Step 4: Special Considerations for Electronic Batch Records (EBR) and Inspection Readiness

The modern pharmaceutical manufacturing environment increasingly relies on electronic documentation systems, including EBRs and electronic Quality Management Systems (eQMS). While fundamentals of GDP remain unchanged, specific considerations apply:

• System Validation and Data Integrity: Electronic systems must be validated according to regulatory expectations such as FDA’s guidance on data integrity to ensure records are accurate, complete, and secure.
• Audit Trails: Every addition, amendment, or deletion should be traceable with user identification, timestamp, and reason for change documented. Such audit trails are key for inspection readiness.
• User Training: Personnel must be adequately trained not only on GMP but also on system-specific requirements to document entries correctly and securely.
• Backup and Archival: Electronic notes and batch records must be regularly backed up with appropriate retention aligned to regulatory timelines and company policy.
• Consistency Across Systems: Cross-referencing between EBR logs and physical records (e.g., equipment maintenance logs) may be necessary for comprehensive investigations.

Adopting these measures supports compliance with EMA Annex 11 and PIC/S guidance concerning computerized systems and reduces risks of data integrity breaches.

Step 5: Review, Approval, and Continuous Improvement of Documentation Practices

Writing the initial note is only part of the documentation lifecycle. Equally important are review, approval, and ongoing training protocols to maintain high-quality GMP documentation standards:

• Quality Review: Notes should be reviewed by a qualified approver, often within pharma QA, to confirm factual accuracy and completeness before finalizing.
• Clarification of Ambiguities: If a note is unclear or incomplete, the reviewer should request immediate clarification or correction, adhering to GDP’s emphasis on accuracy.
• Feedback Loops: Regular team meetings and training sessions can address common documentation errors and promote consistent application of ALCOA+ principles.
• Documentation Audits: Conduct periodic internal audits of batch records and investigation logs to detect weaknesses or non-compliance and implement corrective actions.
• Continuous Training: Ongoing training in GMP documentation practices is essential, especially with evolving digital systems and regulatory updates such as those from ICH Q10 and Q9 quality management principles.

Embedding these review and improvement activities ensures that documentation remains a living, reliable asset for pharma quality management and regulatory compliance.

Conclusion

Writing objective, factual notes in investigations and batch records is a fundamental GMP requirement underpinning product quality assurance, regulatory compliance, and inspection readiness. By adhering to good documentation practice principles—particularly ALCOA+—and following a structured, stepwise approach to preparing, drafting, and reviewing notes, pharma professionals across the US, UK, and EU can ensure documentation integrity.

Integration of these practices within paper and electronic batch records enhances data reliability while facilitating transparent investigations. Ultimately, sound documentation not only supports regulatory submissions and inspections but also strengthens the entire pharmaceutical quality system, contributing to patient safety and product efficacy.

For detailed regulatory text on manufacturing records and GMP documentation, professionals may consult the FDA’s official guidance library and the PIC/S guidance documents, which provide further insights on documentation expectations in a global regulatory context.